BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 22626609)

  • 1. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.
    Ridruejo E; Solano A; Marciano S; Galdame O; Adrover R; Cocozzella D; Delettieres D; Martínez A; Gadano A; Mandó OG; Silva MO
    Ann Hepatol; 2011; 10(4):452-7. PubMed ID: 21911885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
    Domagalski K; Pawłowska M; Tretyn A; Halota W; Pilarczyk M; Smukalska E; Linkowska K; Grzybowski T
    Eur J Clin Microbiol Infect Dis; 2013 Jun; 32(6):745-54. PubMed ID: 23314745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
    Huang CF; Yeh ML; Hsieh MH; Hsieh MY; Lin ZY; Chen SC; Wang LY; Huang JF; Juo SH; Lin YC; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2013 Sep; 28(9):1515-20. PubMed ID: 23560893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
    Ladero JM; Martin EG; Fernández C; Carballo M; Devesa MJ; Martínez C; Suárez A; Díaz-Rubio M; Agúndez JA
    J Gastroenterol Hepatol; 2012 Feb; 27(2):279-85. PubMed ID: 21722179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population.
    Bizid S; Bouali R; Ouedrani A; Mrabet A; Ben Abdallah H; Ghazouani E; Abdelli N
    Tunis Med; 2016 Jan; 94(1):6-11. PubMed ID: 27525598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boceprevir for previously treated chronic HCV genotype 1 infection.
    Bacon BR; Gordon SC; Lawitz E; Marcellin P; Vierling JM; Zeuzem S; Poordad F; Goodman ZD; Sings HL; Boparai N; Burroughs M; Brass CA; Albrecht JK; Esteban R;
    N Engl J Med; 2011 Mar; 364(13):1207-17. PubMed ID: 21449784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
    Lindh M; Lagging M; Arnholm B; Eilard A; Nilsson S; Norkrans G; Söderholm J; Wahlberg T; Wejstål R; Westin J; Hellstrand K
    J Viral Hepat; 2011 Jul; 18(7):e325-31. PubMed ID: 21692944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH; Gordon LA; Fung HB
    Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
    Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
    Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.
    Derbala M; Rizk N; Shebl F; Alkaabi S; Eldweik N; John A; Sharma M; Yaqoob R; Almohanadi M; Butt M; Alejji K
    World J Gastroenterol; 2012 Dec; 18(47):7003-8. PubMed ID: 23323000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
    Jung YK; Kim JH; Ahn SM; Yang JW; Park SJ; Kim JW; Yeon JE; Kwon OS; Kim YS; Choi DJ; Kim JH; Byun KS
    J Clin Gastroenterol; 2013 Aug; 47(7):644-50. PubMed ID: 23442843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.